Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Update

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Based on an average daily volume of 171,900 shares, the short-interest ratio is presently 7.4 days. Approximately 7.4% of the company’s shares are sold short.

Telomir Pharmaceuticals Price Performance

Shares of TELO stock opened at $4.79 on Friday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a fifty day moving average of $4.60 and a 200-day moving average of $4.75.

Institutional Trading of Telomir Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Barclays PLC raised its holdings in shares of Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after acquiring an additional 5,367 shares during the period. Beaird Harris Wealth Management LLC lifted its stake in Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after acquiring an additional 9,950 shares in the last quarter. State Street Corp grew its stake in shares of Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $241,000. Finally, Suncoast Equity Management grew its position in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after purchasing an additional 26,803 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.